Eltrombopag
Thrombopoietin agonist / A novel, orally active, small molecule human thrombopoietin receptor (TPO-R) agonist, EC50=0.27 uM.1,2 Maintains human hematopoietic stem and progenitor cells under inflammatory conditions.3 Promotes DNA repair in human hematopoietic stem and progenitor cells.4 Acts as a powerful chelator of cellular and extracellular iron(III).5 Stimulates hematopoietic stem cells via a TPO-R-independent mechanism involving iron chelation.6
Biochemicals & reagents
496775-61-2
SB-497115
1) Xie et al. (2018), Pharmacological characterization of hetrombopag, a novel orally active human thrombopoietin receptor agoinst; J. Cell. Mol. Med., 22 5367 2) Erickson-Miller et al. (2008), Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist; Stem Cells, 27 424 3) Alvarado et al. (2019), Eltrombopag maintains human hematopoietic stem and progenitor cells under inflammatory conditions mediated by IFN-?; Blood, 133 2043 4) Guenther et al. (2019), Eltrombopag promotes DNA repair in human hematopoietic stem and progenitor cells; Exp. Hematol. 73 1 5) Vlachodimitropoulou et al. (2017), Eltrombopag: a powerful chelator of cellular or extracellular iron (II) alone or combined with a second chelator; Blood, 130 1923 6) Kao et al. (2018), thrombopoietin receptor-independent stimulation of hematopoietic stem cells by eltrombopag; Science Transl. Med., 10 eaas9563
-20°C
TARGET: Chelator; Transcription factor -- PATHWAY: Coagulation; DNA repair; Transcription; Autophagy -- RESEARCH AREA: Stem cells; Cell death; Vesicles -- DISEASE AREA: Cancer